To drill or not to drill, that is the question: nonsurgical treatment of chronic subdural hematoma in the elderly. A systematic review.
CSDH = chronic subdural hematoma
DX = dexamethasone
MMAE = middle meningeal artery embolization
RCT = randomized controlled trial
TXA = tranexamic acid
chronic subdural hematoma
dexamethasone
embolization
endovascular treatment
middle meningeal artery
pharmacotherapy
tranexamic acid
Journal
Neurosurgical focus
ISSN: 1092-0684
Titre abrégé: Neurosurg Focus
Pays: United States
ID NLM: 100896471
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
22
03
2020
accepted:
21
07
2020
entrez:
1
10
2020
pubmed:
2
10
2020
medline:
30
9
2021
Statut:
ppublish
Résumé
Chronic subdural hematoma (CSDH) is one of the most common neurosurgical pathologies, typically affecting the elderly. Its incidence is expected to grow along with the aging population. Surgical drainage represents the treatment of choice; however, postoperative complications and the rate of recurrence are not negligible. For this reason, nonsurgical alternatives (such as middle meningeal artery embolization, steroids, or tranexamic acid administration) are gaining popularity worldwide and need to be carefully evaluated, especially in the elderly population. The authors performed a systematic review according to PRISMA criteria of the studies analyzing the nonsurgical strategies for CSDHs. They collected all papers in the English language published between 1990 and 2019 by searching different medical databases. The chosen keywords were "chronic subdural hematoma," "conservative treatment/management," "pharmacological treatment," "non-surgical," "tranexamic acid," "dexamethasone," "corticosteroid," "glucocorticoid," "middle meningeal artery," "endovascular treatment," and "embolization." The authors ultimately collected 15 articles regarding the pharmacological management of CSDHs matching the criteria, and 14 papers included the endovascular treatment. The results showed that surgery still represents the mainstay in cases of symptomatic patients with large CSDHs; however, adjuvant and alternative therapies can be effective and safe in a carefully selected population. Their inclusion in new guidelines is advisable.
Identifiants
pubmed: 33002869
doi: 10.3171/2020.7.FOCUS20237
pii: 2020.7.FOCUS20237
doi:
pii:
Substances chimiques
Tranexamic Acid
6T84R30KC1
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM